Chardan Capital Raises Earnings Estimates for Tourmaline Bio

Tourmaline Bio, Inc. (NASDAQ:TRML) – Stock analysts at Chardan Capital upped their FY2025 earnings per share estimates for shares of Tourmaline Bio in a research report issued to clients and investors on Monday, May 5th. Chardan Capital analyst D. Gataulin now anticipates that the company will earn ($3.93) per share for the year, up from their prior estimate of ($4.10). Chardan Capital currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Tourmaline Bio’s current full-year earnings is ($3.02) per share. Chardan Capital also issued estimates for Tourmaline Bio’s FY2026 earnings at ($4.72) EPS.

Other analysts have also issued research reports about the company. Lifesci Capital initiated coverage on Tourmaline Bio in a report on Monday, February 24th. They set an “outperform” rating and a $58.00 price target on the stock. Wedbush raised their target price on shares of Tourmaline Bio from $42.00 to $43.00 and gave the stock an “outperform” rating in a report on Friday, March 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Tourmaline Bio in a report on Monday. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $49.33.

Tourmaline Bio Trading Up 2.3 %

TRML opened at $15.74 on Thursday. Tourmaline Bio has a 12 month low of $11.56 and a 12 month high of $29.79. The stock has a 50-day moving average of $15.43 and a 200 day moving average of $18.87. The firm has a market cap of $404.28 million, a P/E ratio of -5.58 and a beta of 2.11.

Tourmaline Bio (NASDAQ:TRML) last released its quarterly earnings data on Friday, May 2nd. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.02.

Institutional Trading of Tourmaline Bio

A number of large investors have recently made changes to their positions in the stock. Rhumbline Advisers boosted its position in Tourmaline Bio by 2.1% in the 4th quarter. Rhumbline Advisers now owns 35,591 shares of the company’s stock valued at $722,000 after buying an additional 718 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Tourmaline Bio by 3.4% in the fourth quarter. SG Americas Securities LLC now owns 34,812 shares of the company’s stock valued at $706,000 after purchasing an additional 1,140 shares during the period. Invesco Ltd. grew its stake in Tourmaline Bio by 10.8% in the fourth quarter. Invesco Ltd. now owns 12,155 shares of the company’s stock worth $247,000 after purchasing an additional 1,181 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Tourmaline Bio by 297.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company’s stock worth $33,000 after purchasing an additional 1,232 shares in the last quarter. Finally, Brooklyn Investment Group purchased a new position in Tourmaline Bio during the 4th quarter worth $32,000. 91.89% of the stock is owned by hedge funds and other institutional investors.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.